{
    "nctId": "NCT05841849",
    "briefTitle": "Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer",
    "officialTitle": "Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, Chemotherapy-induced Nausea and Vomiting",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 1028,
    "primaryOutcomeMeasure": "complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, age 18-70 years.\n* Confirmed pathology suggested primary invasive breast adenocarcinoma; Presence of adjuvant chemotherapy or neoadjuvant chemotherapy indications according to clinical guidelines.\n* No other malignant tumor or other chemotherapy\n* No prior treatment for present breast cancer onset\n* ECOG physical status score 0 to 1\n* Hematological examination before treatment should meet: white blood cell count (WBC) \u2265 4.0\u00d710\\^9/L, neutrophil count (ANC) \u2265 1.5\u00d710\\^9/L, platelet count (PLT) \u2265 100\u00d710\\^9/L; hemoglobin (Hb) \u2265 90g/L; AST (sGOT), ALT (sGPT) \u2264 1.5 times the normal value upper limit, creatinine \u2264 1.5 times the upper limit of normal value, total bilirubin \u2264 1.5 times the upper limit of normal value.\n* No serious impairment of heart, liver, kidney and other important organ functions.\n\nExclusion Criteria:\n\n* Unwilling or unable to use an acceptable method of contraception for up to and including 8 weeks after the final dose of the test drug.\n* Women during pregnancy and breastfeeding after pregnancy.\n* Women with proven distant metastases of breast cancer.\n* Patients with proven sensory or motor nerve disease.\n* Definite cardiovascular disease, severe co-morbidity or active infection, including known HIV infection.\n* Patients who need long-term anticoagulant drugs for cardiovascular or thrombotic diseases.\n* History of other tumors.\n* Allergic to the study drug or its excipients, etc.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}